N6-methyladenosine (m⁶A) is the most abundant internal modification on RNA. It is a dynamical and reversible process, which is regulated by m⁶A methyltransferase and m⁶A demethylase. The m⁶A modified RNA can be specifically recognized by the m⁶A reader, leading to RNA splicing, maturation, degradation or translation. The abnormality of m⁶A RNA modification is closely related to a variety of biological processes, especially the occurrence and development of tumors. Recent studies have shown that m⁶A RNA modification is involved in the pathogenesis of skin cancers. However, the precise molecular mechanisms of m⁶A-mediated cutaneous tumorigenesis have not been fully elucidated. Therefore, this review will summarize the biological characteristics of m⁶A modification, its regulatory role and mechanism in skin cancers, and the recent research progress of m⁶A-related molecular drugs, aiming to provide new ideas for clinical diagnosis and targeted therapy of cutaneous cancers.